Lead Product(s): OPC1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OPC1
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021
Lineage and Neurgain will collaborate on the clinical testing of Neurgain’s novel Parenchymal Delivery Injection system, OPC1 , which is designed to allow for the administration of cells to the spinal cord without stopping the patient’s respiration.